News

IM Cannabis Corp Celebrates Impressive 50% Q3 Revenue Surge

IM Cannabis Corp Celebrates Impressive 50% Q3 Revenue Surge

IM Cannabis Corp Reports Record Growth in Q3 2024

IM Cannabis Corp (NASDAQ: IMCC) is thrilled to share its preliminary financial results for the third quarter of 2024, revealing an impressive 50% growth in revenues compared to the previous quarter. This outstanding performance highlights the company's strategic execution and growing demand for its premium cannabis products.

Significant Revenue Increase

The company's subsidiary, IMC Germany, achieved preliminary sales of approximately CAD$ 3.5 million in the second quarter. Thanks to increased consumer interest following cannabis legalization, revenue soared this past quarter, demonstrating the effectiveness of IMC's operational strategies.

Strategic Objectives Driving Demand

Since the new cannabis regulations were put into effect, IM Cannabis has focused on strengthening its supply chain to meet rising consumer needs. CEO Oren Shuster stated, "One of our main goals has been to ensure that our supply chain could support increased demand. This preliminary 50% growth is evidence of our successful efforts in this area." His enthusiasm for the Q3 performance underscores not only the financial success but also the dedication embodied by the entire IM Cannabis team.

Market Growth Following Legal Changes

The medical cannabis market in Germany has seen a considerable expansion following the government's moves towards legalization. IMC's readiness to adapt to these changes has positioned the company favorably as the market continues to grow.

About IM Cannabis Corp.

IM Cannabis Corp is an international cannabis provider, specializing in high-quality cannabis products for medical patients primarily in Israel and Germany. The company has strategically redirected resources to achieve sustainable growth in these significant markets, ensuring compliance with stringent industry regulations while enhancing its market presence.

Innovative Ecosystem Operations

In Israel, IM Cannabis collaborates with Focus Medical Herbs Ltd., which supports distribution to medical clients through years of data and patient insights. This collaborative framework is key to the successful delivery of IMC products, ensuring quality control and customer satisfaction.

Future Outlook for IM Cannabis

The robust performance of IMC during Q3 is a promising indicator of future success as the company continues to strengthen its operations and adapt to market demands. With a focus on responsible growth and industry compliance, IM Cannabis Corpaims to bolster its brand power and expand its reach both nationally and internationally.

Fiscal Responsibility and Customer Commitment

IM Cannabis remains dedicated to maintaining fiscal responsibility, which is critical for navigating the complexities of the cannabis industry. The company emphasizes the importance of fulfilling customer commitments while pursuing innovative product offerings and operational efficiency.

Company Contact Information

For investor inquiries, please contact Anna Taranko, Director of Investor & Public Relations at IM Cannabis Corp, available at +49 157 80554338 or via email at a.taranko@imcannabis.de. CEO Oren Shuster can be reached at info@imcannabis.com.

Frequently Asked Questions

What is IM Cannabis Corp?

IM Cannabis Corp is an international cannabis company that provides premium cannabis products to medical patients, mainly in Israel and Germany.

What was the revenue growth percentage reported in Q3?

IM Cannabis reported a remarkable 50% increase in revenue in the third quarter of 2024 compared to the previous quarter.

What drives the demand for IMC products?

The increase in market demand for cannabis products is primarily driven by the recent legalization changes and the company's effective supply chain management.

How does IM Cannabis ensure product quality?

IM Cannabis employs a robust supply chain system and collaborates with partners like Focus Medical Herbs Ltd. to maintain high standards in product delivery and quality control.

Who can I contact for more information about IM Cannabis?

For inquiries, you may contact Anna Taranko, Director of Investor Relations, or CEO Oren Shuster through the provided email addresses.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 469

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 181

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 848

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 63

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 117

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 423

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 734

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 176

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading

Top 5 Most Recently Viewed Articles

MacGregor's Bold Play: RoRo Tech for TT-Line's Ferries

Updated Category News Views 51

A Green Wave in the Baltic It looks like MacGregor's betting big on the future of maritime transport, and they're putting their chips down on TT-Line's next-gen battery-hybrid LNG ferries. With a contract fresh out of the oven, they've signed up to kit out these eco-warriors with a range of RoRo equipment. And let me tell you, this is no piddly order—by any stretch,...

Continue Reading
WAVE Life Sciences: Rising Share Value Amid DMD Innovations

Updated Category News Views 50

Recent Developments at WAVE Life Sciences B.Riley has maintained a Buy rating on WAVE Life Sciences (NASDAQ: WVE) and raised the price target to $19 from $11. This adjustment comes after the promising announcement regarding the company's Duchenne muscular dystrophy (DMD) drug candidate, WVE-N531. Promising DMD Drug Candidate The company's analyst highlighted an increase...

Continue Reading
First American Uranium Successfully Secures $2.86 Million Funding

Updated Category News Views 143

First American Uranium Secures Oversubscribed Financing First American Uranium Inc. is thrilled to announce the closing of its oversubscribed flow-through share financing, having raised an impressive $2.86 million from issuing a total of 2,073,262 flow-through shares. Each share was priced at $1.38, exceeding initial expectations. Funding Utilization for Exploration The...

Continue Reading
Community Healthcare Trust Reports Q2 Financial Results

Updated Category News Views 161

Summary of Financial Results Community Healthcare Trust Incorporated (NYSE: CHCT) recently announced its financial performance for the quarter ending June 30, 2025. The company reported a net loss of approximately $12.6 million or $0.50 per diluted common share. The funds from operations ("FFO") and adjusted funds from operations ("AFFO") during this period amounted to...

Continue Reading
Neuberger Fund Ups Distribution Amid Market Challenges

Updated Category News Views 169

Neuberger Boosts Distribution: What's Driving This? I ain't about to sugarcoat it: the Neuberger Next Generation Connectivity Fund (NYSE: NBXG) decided to jack up its monthly distribution rate to $0.132 per share. This announcement, hitting wallets on November 30, 2026, has a record and ex-date of November 16. Now, that's a good ol' reliable payout for folks holding NBXG...

Continue Reading